Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.

Urologic oncology - 1 Mar 2023

Gerald Thomas, Margulis Vitaly, Meng Xiaosong, Bagrodia Aditya, Cole Suzanne, Qin Qian, Call S Greg, Mauer Elizabeth, Lotan Yair, Woldu Solomon L

Abstract excerpt

BACKGROUND: Recent targeted therapies for advanced and metastatic urothelial cancer have generated enthusiasm, but the actionable genomic landscape of early-stage disease remains largely unknown. Here, we utilized a large, real-world cohort to comprehensively investigate the incidence of genetic alterations with potential therapeutic implications at all stages of bladder cancer. MATERIALS AND METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Genomics

Share to Mutation

Share to Urinary Bladder Neoplasms

Share to Xeroderma Pigmentosum Group D Protein

Source

Identifiers

PMID: 36653279
DOI: 10.1016/j.urolonc.2022.12.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.PMID 36653279Read ↗

Similar genetic profile in early and late stage urothelial tract cancer.Semantic proximity Read ↗

The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers.Semantic proximity Read ↗

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.Semantic proximity Read ↗

Molecular Profiling of Bladder Adenocarcinoma Using a National Genomics RepositorySemantic proximity Read ↗

Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics.Semantic proximity Read ↗

Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.Semantic proximity Read ↗

Genomic Characterization of Upper Tract Urothelial Carcinoma.Semantic proximity Read ↗

Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.Semantic proximity Read ↗

Comprehensive genomic characterization of early-stage bladder cancer.Semantic proximity Read ↗

Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing.Semantic proximity Read ↗

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.Semantic proximity Read ↗

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.